Stock Events

Nxera Pharma. 

$10.53
3
+$0+0% Thursday 20:00

Statistics

Day High
9.78
Day Low
9.6
52W High
13.43
52W Low
8.56
Volume
800
Avg. Volume
79
Mkt Cap
946.87M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Jun 15
$0.02
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

9MayConfirmed
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2023
Q1 2024
-25.39
-7.52
10.34
28.21
Expected EPS
0.124589593077
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SOLTF. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap169.83B
Pfizer is a major player in the pharmaceutical industry, directly competing in various therapeutic areas covered by Nxera Pharma.
Merck &
MRK
Mkt Cap318.55B
Merck operates globally in the pharmaceutical sector, offering products that compete with Nxera Pharma's range, especially in prescription drugs.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson offers a broad range of health products that compete across multiple segments, including those targeted by Nxera Pharma.
GSK
GSK
Mkt Cap81.55B
GlaxoSmithKline competes in the pharmaceutical and healthcare sectors, with overlapping interests in medications and therapies.
Novartis
NVS
Mkt Cap232.42B
Novartis is known for its extensive research and development in pharmaceuticals, competing with Nxera Pharma in innovation and market share.
Abbvie
ABBV
Mkt Cap304.29B
AbbVie competes in the global pharmaceutical market, particularly in areas of chronic diseases, directly challenging Nxera Pharma's product lines.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol-Myers Squibb is a key competitor in the pharmaceutical industry, with a strong presence in drug development and marketing.
Sanofi
SNY
Mkt Cap128.21B
Sanofi operates internationally, offering products that compete in the same therapeutic areas as Nxera Pharma.
Lilly(Eli) &
LLY
Mkt Cap814.94B
Eli Lilly and Company is a major pharmaceutical company with competitive products in the diabetes and cancer sectors, relevant to Nxera Pharma's interests.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.04B
Teva Pharmaceutical Industries is a global competitor, particularly in the generic pharmaceuticals market, impacting Nxera Pharma's market dynamics.

About

Pharmaceuticals: Generic
Health Technology
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of HTL0022562, a calcitonin gene related peptide antagonist, which is in Phase I clinical study; HTL0016878 for neurological diseases; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; and TMP301 and BHV3100 for neurological disorders, which is in clinical trials. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.
Show more...
CEO
Shinichi Tamura
Employees
350
Country
JP
ISIN
JP3431300007
WKN
000A0B7EK

Listings

TSE
Japan
4565.TSE
F
DE
JSS.F
OTCM
US
SOLTF